GeoVax Accelerates GEO-MVA Vaccine Development Amid Global Mpox Crisis

GeoVax Labs, Inc. has announced an accelerated development strategy for its GEO-MVA Mpox vaccine candidate, responding to the World Health Organization's reaffirmation of Mpox as a Public Health Emergency of International Concern and a significant surge in cases, particularly in Africa. The European Medicines Agency's favorable scientific advice supports a streamlined regulatory pathway for the vaccine, emphasizing the global need for diversified and scalable vaccine platforms amidst critical shortages and the spread of more virulent Mpox strains.

The global Mpox crisis has seen over 21,000 confirmed cases in Africa in 2025 alone, with healthcare systems in countries like Sierra Leone, Malawi, and the Democratic Republic of the Congo under severe strain. The emergence of Clade I Mpox variants, noted for their greater severity and transmissibility, has further complicated the situation, with cases now confirmed in China, the United Kingdom, Italy, and the United States.

GeoVax's response includes accelerating clinical development, advancing manufacturing platforms for large-scale production, and engaging in international collaboration to ensure equitable vaccine access. The company's CEO, David Dodd, highlighted the urgency of addressing the crisis with scalable solutions like GEO-MVA, which is poised to meet global needs through regulatory momentum and a commitment to equitable access.